Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Features

Features
Supercomputers used to go from genome to lead in under a month

25 Jan 06

Genomics and proteomics comprise a fundamental area of bioinformatics however exploiting the wealth of information gained using such disciplines remains a rate limiting step in the drug discovery process. Today’s edition of DailyUpdates (Jan 25th 2005) describes ground breaking work that has allowed researchers to identify candidate therapeutics for the treatment of SARs virus infection in under a month using the virus genome as a starting point
LeadDiscovery

BAFF & APRIL: Emerging Targets for Autoimmune & Cancer Therapeutics

18 Jan 06

In 1999 Human Genome Sciences researchers published a study in the journal Science describing a new member of the TNF super-family which they named BLyS. Since that time our understanding of this protein, also known as BAFF, and its homologue APRIL has progressed rapidly. The BAFF sub-family has emerged as a candidate target for therapies of various autoimmune diseases and hematological cancers with breathtaking speed.
LeadDiscovery

Ferriprox prevents heart failure deaths in thalassaemia

16 Jan 06

A new study shows the oral iron-chelator Ferriprox (deferiprone) prevents patients with thalassaemia experiencing heart complications and dying of heart failure. Patients with the condition require frequent blood transfusions with the unwanted effect of excess iron that can build up in organs and endocrine glands. Iron overload in the heart can produce fatal complications so effective treatment with iron chelation therapy to remove iron is vital. The finding that an oral treatment achieves bett
Olwen Glynn Owen - PharmiWeb Field Reporter

2006 –Near Term Expectations for Clinical Research

11 Jan 06

There is little mystery about what the next few years hold for the clinical research industry –it comes down to one word: speed. It is all about speed. The gauntlet has been thrown down and the companies that are able to demonstrate an effective and consistent approach to truncating the timeline of clinical trials will be very successful.
Brian S. Robinson

The Rough Guide to Electronic Data Capture

11 Jan 06

Electronic Data Capture (EDC), three little words that can divide the clinical research community like few others. To some, EDC is a panacea for all the troubles and rising costs of the clinical development process, whilst to others it spells broken promises, and forms the butt of many less than flattering anecdotes.
Andrew Salomon

Charity = Free Job Postings!

11 Jan 06

Free Job Postings for UK Charity Organisations in the Healthcare Sector.
Mike Wood

Blog your Jobs

10 Jan 06

New Blog for Jobs
Mike Wood

Rapid testing vital in tackling Bird Flu

04 Jan 06

Dr Adam Meijer of the Netherlands-based European Influenza Surveillance Scheme (EISS)§ has highlighted the vital role rapid testing must play in combating the global threat of bird flu. Dr Meijer makes his observations in the January issue of Expert Review of Molecular Diagnostics.
Simon Boisseau

Exjade - first oral treatment for iron overload - will make life easier for patients needing regular blood transfusion

22 Dec 05

New data presented at the American Society of Hematology meeting in Atlanta this month suggest the problems associated with iron overload in frequently-transfused patients can now be managed simply with an oral treatment rather than continuous infusions of several hours duration.
Olwen Glynn Owen PharmiWeb Field Reporter

Glivec improves long-term survival prospects for chronic myeloid leukaemia patients

21 Dec 05

Most patients who develop chronic myeloid leukaemia (CML) can now expect to live more than 20 years from diagnosis if they are treated with the tyrosine kinase inhibitor (TKI) Glivec (imatinib) according to haematologists involved in the IRIS (International Randomized Interferon versus STI571) study. Before availability of current treatments, median survival from diagnosis was 3.5 years.
Olwen Glynn Owen - PharmiWeb Field Reporter

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.